Replies to post #118015 on Biotech Values

[DewDiligence]

It’s a non-trivial opportunity, but is it enough to make the addressable worldwide market for HCV drugs bigger in 2021 than it is today? I highly doubt it because there isn’t a high enough rate of new infections to offset the expected cures.